GSK245 (DDD1305143)
Progress development of the GSK245 (DDD1305143) compound for leishmaniasis.
current phase of drug development
updated 21 Mar 2024
In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis: GSK245 (formerly GSK245/DDD1305143) and DNDi-6899 (formerly GSK899/DDD853651). The compounds were developed through a collaboration between the GSK Global Health Unit and the Drug Discovery Unit at the University of Dundee, with co-funding support from Wellcome. In February 2020, DNDi and GSK signed a development and license agreement for GSK245 (DDD1305143).
Project updates
2023
The development of GSK245 continues and GSK is the sponsor of a Phase I clinical study in healthy volunteers in the UK. The single ascending dose part of the study has been completed. This drug candidate shares a similar mode of action with LXE408, the frontrunner in DNDi’s portfolio of NCEs under development for leishmaniasis.
2022
GSK put the Phase I single ascending dose trial of GSK245 (DDD1305143) on hold in 2022 to perform additional investigations into the compound’s complex pharmacokinetics. The Phase I study of the compound is expected to resume and complete in early 2023.
2021
A Phase I combined single ascending dose and multiple ascending dose study of GSK3494245/DDD1305143 in healthy volunteers began in late 2020 and continued in 2021, but faced delays due to the COVID-19 pandemic. It is now expected to be completed by mid-2022.
2020
A Phase I single ascending dose study of GSK3494245/DDD1305143 in healthy volunteers began in late 2020 and is expected to be completed by Q3 2021.
2019
A Phase I single ascending dose study of GSK3494245/DDD1305143 is planned to start in late 2020.
2018
GSK3494245/DDD1305143 is currently under review to assess the feasibility of proceeding to a Phase I study.
News & resources
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.
